Journal of Pharmaceutical Sciences & Emerging Drugs

Synthesis, Pharmacokinetics, Pharmacodynamics, Dosing, Stability, Safety and Efficacy of Orphan Nano Drugs to Treat High Cholesterol and Related Conditions and to Prevent Cardiovascular Disease Under Synchrotron Radiation

Alireza Heidari

Orphan Nano drugs such as Rituxan, Revlimid, Soliris, Afinitor, Tasigna, Velcade, Avonex, Alimta, Yervoy, Sprycel, Rebif, Kalydeco, Jakavi, Sutent, Kyprolis, Kogenate, NovoSeven, Nexavar, Copaxone, Ibrutinib and their derivatives are versatile intermediates in the field of pharmaceuticals, cosmetics and perfumes. Further, Rituxan, Revlimid, Soliris, Afinitor, Tasigna, Velcade, Avonex, Alimta, Yervoy, Sprycel, Rebif, Kalydeco, Jakavi, Sutent, Kyprolis, Kogenate, NovoSeven, Nexavar, Copaxone, Ibrutinib and their derivatives are important derivatives of Orphan Nano drugs, which have received considerable attention in recent years because of their wide range of biological and pharmaceutical activities. Several methods have been reported for the synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of these Nano compounds in literature. However, most of these methods use solvents which make the workup procedure complicated or use expensive catalysts and high temperatures. Following our continued interests in the synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of heterocyclic Nano compounds, we studied the synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of Orphan Nano drugs to treat high cholesterol and related conditions and to prevent cardiovascular disease under synchrotron radiation using a one– pot three component reaction under solvent free condition and a new base catalyst. The reaction gave the desired products in low reaction time and excellent yields.